TS-015264 — Tumor-targeting oncolytic virus is able to kill cancer cells while sparing normal cells and encodes anti-angiogenic factors that reduced blood vessel formation and may modulate innate immune response.
Glioblastoma is the most common primary malignant brain tumor, with a median survival of less than 15 months from diagnosis. Current standard of care combines surgical resection, with radiation and chemotherapy. However, many patients recur with resistant tumors that require alternative treatments…
